Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trypanosoma cruzi | 13 | 2023 | 157 | 1.220 |
Why?
|
| Chagas Disease | 7 | 2023 | 104 | 0.720 |
Why?
|
| Proteome | 4 | 2024 | 152 | 0.620 |
Why?
|
| Protozoan Proteins | 7 | 2021 | 191 | 0.520 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2026 | 10 | 0.490 |
Why?
|
| Electronic Health Records | 3 | 2026 | 108 | 0.460 |
Why?
|
| Thrombospondin 1 | 3 | 2022 | 23 | 0.440 |
Why?
|
| RNA, Small Interfering | 4 | 2021 | 436 | 0.430 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 1723 | 0.410 |
Why?
|
| Proteomics | 6 | 2024 | 378 | 0.400 |
Why?
|
| Genomics | 3 | 2023 | 293 | 0.360 |
Why?
|
| Semen | 2 | 2021 | 57 | 0.330 |
Why?
|
| Trypanosoma brucei brucei | 2 | 2021 | 82 | 0.300 |
Why?
|
| Medical History Taking | 2 | 2026 | 38 | 0.300 |
Why?
|
| Exosomes | 3 | 2019 | 126 | 0.280 |
Why?
|
| Porphyromonas gingivalis | 3 | 2024 | 40 | 0.260 |
Why?
|
| Humans | 37 | 2026 | 43102 | 0.260 |
Why?
|
| Benzo(a)pyrene | 2 | 2021 | 128 | 0.240 |
Why?
|
| Cocaine | 2 | 2021 | 251 | 0.240 |
Why?
|
| Monocytes | 2 | 2021 | 277 | 0.220 |
Why?
|
| Epithelial Cells | 3 | 2018 | 434 | 0.210 |
Why?
|
| Dental Plaque | 1 | 2024 | 13 | 0.210 |
Why?
|
| Streptococcus | 1 | 2024 | 18 | 0.210 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2022 | 60 | 0.210 |
Why?
|
| Periodontitis | 1 | 2024 | 62 | 0.200 |
Why?
|
| Protein Folding | 1 | 2024 | 123 | 0.200 |
Why?
|
| Protein Conformation | 1 | 2024 | 416 | 0.190 |
Why?
|
| HIV Infections | 4 | 2021 | 2586 | 0.190 |
Why?
|
| Gastritis | 1 | 2022 | 13 | 0.190 |
Why?
|
| Pancreatitis | 1 | 2022 | 21 | 0.180 |
Why?
|
| Medical Informatics | 1 | 2022 | 25 | 0.180 |
Why?
|
| Hypercalcemia | 1 | 2022 | 13 | 0.180 |
Why?
|
| Trypanosomiasis, African | 1 | 2021 | 22 | 0.180 |
Why?
|
| Chemotaxis | 1 | 2021 | 68 | 0.180 |
Why?
|
| HIV-1 | 2 | 2019 | 755 | 0.180 |
Why?
|
| Metformin | 1 | 2022 | 75 | 0.180 |
Why?
|
| Neoplasms | 3 | 2026 | 1377 | 0.170 |
Why?
|
| beta Catenin | 1 | 2022 | 78 | 0.170 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 1092 | 0.170 |
Why?
|
| Genome | 1 | 2022 | 149 | 0.170 |
Why?
|
| Gene Regulatory Networks | 4 | 2021 | 149 | 0.170 |
Why?
|
| Endothelial Cells | 2 | 2022 | 329 | 0.160 |
Why?
|
| Myoblasts | 1 | 2020 | 30 | 0.160 |
Why?
|
| Obstetric Labor, Premature | 2 | 2010 | 9 | 0.160 |
Why?
|
| Cell Cycle | 1 | 2021 | 346 | 0.160 |
Why?
|
| Blood | 1 | 2019 | 37 | 0.160 |
Why?
|
| Female | 14 | 2026 | 24698 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 44 | 0.150 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2019 | 49 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 129 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2022 | 1271 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 223 | 0.140 |
Why?
|
| Homeostasis | 1 | 2019 | 192 | 0.140 |
Why?
|
| Myocardium | 1 | 2020 | 263 | 0.140 |
Why?
|
| Myocytes, Cardiac | 2 | 2020 | 183 | 0.140 |
Why?
|
| Colon | 1 | 2018 | 120 | 0.130 |
Why?
|
| Cell Nucleus | 2 | 2016 | 383 | 0.130 |
Why?
|
| Periodontal Diseases | 1 | 2017 | 49 | 0.130 |
Why?
|
| Phosphoproteins | 1 | 2018 | 206 | 0.130 |
Why?
|
| Mouth | 1 | 2017 | 54 | 0.130 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2016 | 6 | 0.130 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2016 | 11 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2026 | 734 | 0.120 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2016 | 8 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 704 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 518 | 0.120 |
Why?
|
| Male | 11 | 2026 | 23409 | 0.110 |
Why?
|
| Transport Vesicles | 1 | 2014 | 22 | 0.110 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 1 | 2014 | 8 | 0.110 |
Why?
|
| Fimbriae, Bacterial | 1 | 2014 | 30 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2014 | 62 | 0.110 |
Why?
|
| Virus Integration | 1 | 2015 | 65 | 0.110 |
Why?
|
| Genetic Counseling | 2 | 2026 | 15 | 0.110 |
Why?
|
| Phosphorus-Oxygen Lyases | 1 | 2014 | 7 | 0.110 |
Why?
|
| Mice | 8 | 2022 | 6644 | 0.110 |
Why?
|
| Nitric Oxide | 1 | 2017 | 386 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2014 | 165 | 0.100 |
Why?
|
| Animals | 12 | 2022 | 16992 | 0.100 |
Why?
|
| Capsid Proteins | 1 | 2014 | 76 | 0.100 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2014 | 49 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 968 | 0.100 |
Why?
|
| Cell Membrane | 2 | 2013 | 403 | 0.100 |
Why?
|
| alpha-Defensins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Flagella | 1 | 2013 | 32 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 279 | 0.100 |
Why?
|
| Locomotion | 1 | 2013 | 105 | 0.100 |
Why?
|
| Calreticulin | 1 | 2012 | 8 | 0.090 |
Why?
|
| Escherichia coli Proteins | 1 | 2014 | 133 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 2676 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2026 | 863 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2012 | 238 | 0.090 |
Why?
|
| Models, Biological | 3 | 2018 | 712 | 0.090 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 36 | 0.090 |
Why?
|
| Fetus | 1 | 2012 | 101 | 0.090 |
Why?
|
| Heart | 2 | 2023 | 184 | 0.080 |
Why?
|
| Prostate | 1 | 2011 | 155 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 749 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 314 | 0.080 |
Why?
|
| Acinetobacter Infections | 1 | 2010 | 29 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2010 | 36 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 65 | 0.080 |
Why?
|
| Cross Infection | 1 | 2010 | 48 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2021 | 986 | 0.080 |
Why?
|
| Acinetobacter baumannii | 1 | 2010 | 40 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2010 | 92 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 91 | 0.070 |
Why?
|
| RNA Interference | 2 | 2010 | 247 | 0.070 |
Why?
|
| Leukocytes | 1 | 2009 | 80 | 0.070 |
Why?
|
| Rats | 4 | 2022 | 3735 | 0.070 |
Why?
|
| Middle Aged | 5 | 2026 | 12222 | 0.070 |
Why?
|
| Aged | 4 | 2026 | 8214 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 5080 | 0.070 |
Why?
|
| Adult | 5 | 2026 | 13872 | 0.060 |
Why?
|
| Myoblasts, Cardiac | 1 | 2006 | 4 | 0.060 |
Why?
|
| Mitochondria | 2 | 2021 | 523 | 0.060 |
Why?
|
| Casein Kinase II | 1 | 2006 | 17 | 0.060 |
Why?
|
| Neoplasm Proteins | 2 | 2022 | 228 | 0.060 |
Why?
|
| Viral Load | 2 | 2019 | 348 | 0.060 |
Why?
|
| Laminin | 1 | 2006 | 58 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2006 | 154 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2026 | 259 | 0.060 |
Why?
|
| Fimbriae Proteins | 2 | 2014 | 25 | 0.050 |
Why?
|
| Neuraminidase | 2 | 2006 | 9 | 0.050 |
Why?
|
| Cell Line | 2 | 2021 | 1410 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 54 | 0.050 |
Why?
|
| Nitrogen | 1 | 2005 | 84 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2020 | 2157 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 199 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 1070 | 0.050 |
Why?
|
| Gene Expression | 3 | 2011 | 701 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 667 | 0.050 |
Why?
|
| Castration | 1 | 2022 | 34 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1621 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 117 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 259 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 694 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2006 | 561 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 155 | 0.050 |
Why?
|
| Endothelium | 1 | 2022 | 28 | 0.050 |
Why?
|
| Androgens | 1 | 2022 | 106 | 0.050 |
Why?
|
| DNA, Kinetoplast | 1 | 2021 | 4 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 75 | 0.040 |
Why?
|
| Disclosure | 1 | 2022 | 39 | 0.040 |
Why?
|
| Population Groups | 1 | 2022 | 59 | 0.040 |
Why?
|
| Genome, Human | 1 | 2022 | 144 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 144 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 310 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 281 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 90 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 216 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 244 | 0.040 |
Why?
|
| Pregnancy | 3 | 2012 | 1772 | 0.040 |
Why?
|
| Cell Movement | 2 | 2016 | 655 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2021 | 47 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 53 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1124 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 220 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2853 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 385 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 983 | 0.040 |
Why?
|
| Tennessee | 1 | 2019 | 93 | 0.040 |
Why?
|
| Adenylate Kinase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 68 | 0.040 |
Why?
|
| Adolescent | 2 | 2021 | 6081 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 491 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 737 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2020 | 192 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2544 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 213 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1999 | 125 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 1999 | 124 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2022 | 1035 | 0.040 |
Why?
|
| DNA Damage | 1 | 2021 | 356 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2019 | 139 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 518 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 241 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2019 | 321 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1869 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 195 | 0.030 |
Why?
|
| Gastrointestinal Motility | 1 | 2017 | 20 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 3994 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 561 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 51 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 1180 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 1542 | 0.030 |
Why?
|
| Saliva | 1 | 2017 | 119 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 102 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 131 | 0.030 |
Why?
|
| Vesiculovirus | 1 | 2015 | 5 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 2015 | 13 | 0.030 |
Why?
|
| Biofilms | 1 | 2017 | 184 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 169 | 0.030 |
Why?
|
| Proviruses | 1 | 2015 | 35 | 0.030 |
Why?
|
| Macrophages | 1 | 1999 | 529 | 0.030 |
Why?
|
| Virion | 1 | 2015 | 75 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1455 | 0.030 |
Why?
|
| Ligands | 2 | 2010 | 388 | 0.030 |
Why?
|
| Endocytosis | 1 | 2015 | 118 | 0.030 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 102 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2014 | 41 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 249 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 296 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 40 | 0.030 |
Why?
|
| Virulence | 1 | 2014 | 246 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 166 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2019 | 1003 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2015 | 311 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 508 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2010 | 536 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 171 | 0.020 |
Why?
|
| Plasminogen | 1 | 2012 | 10 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 652 | 0.020 |
Why?
|
| Life Cycle Stages | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 127 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 107 | 0.020 |
Why?
|
| Systole | 1 | 2012 | 67 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2012 | 108 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 678 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2012 | 75 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 327 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 197 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 290 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 69 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 42 | 0.020 |
Why?
|
| Uterus | 1 | 2010 | 52 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 44 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 280 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 429 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 209 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2012 | 192 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 456 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 77 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 883 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 245 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 490 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 318 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1177 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 160 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2009 | 77 | 0.020 |
Why?
|
| Urban Population | 1 | 2010 | 374 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 440 | 0.020 |
Why?
|
| Premature Birth | 1 | 2009 | 95 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 611 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 592 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 196 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 241 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 432 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 512 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2006 | 168 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2006 | 219 | 0.010 |
Why?
|
| Antigens, Protozoan | 1 | 2006 | 74 | 0.010 |
Why?
|
| Prions | 1 | 2005 | 23 | 0.010 |
Why?
|
| Virulence Factors | 1 | 2006 | 125 | 0.010 |
Why?
|
| Mathematics | 1 | 2005 | 57 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 90 | 0.010 |
Why?
|
| Glutathione Peroxidase | 1 | 2005 | 112 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 110 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2005 | 273 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 3156 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 735 | 0.010 |
Why?
|
| Maleimides | 1 | 1999 | 12 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1999 | 52 | 0.010 |
Why?
|
| Cytosol | 1 | 1999 | 97 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 462 | 0.010 |
Why?
|
| Indoles | 1 | 1999 | 187 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1999 | 306 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 458 | 0.010 |
Why?
|